GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.

GW has developed an oral formulation of purified cannabidiol (CBD), initially approved as EPIDIOLEX® in the U.S. by the U.S. Food and Drug Administration (FDA).  We initially launched EPIDIOLEX in the U.S. in November 2018 for the treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients 2 years of age and older, two rare and severe early-onset, drug-resistant epilepsy syndromes. In July 2020, the FDA expanded the approval of Epidiolex, adding a new indication of seizures associated with Tuberous Sclerosis Complex or TSC in patients one year of age and older.  Along with this new indication, the age range was expanded to include patients one year of age and older who experience seizures associated with LGS or Dravet syndrome. 

Jazz Pharmaceuticals acquired the company in May 2021.